A PYMNTS Company

India: Fines imposed after restricted drug supply investigation

By  |  August 2, 2016

The Competition Commission of India fined drugmaker Lupin Ltd and a Karnataka chemists’ body on Tuesday in a case involving restricted drug supply in the southern state.

    Get the Full Story

    Complete the form to unlock this article and enjoy unlimited free access to all PYMNTS content — no additional logins required.

    yesSubscribe to our daily newsletter, PYMNTS Today.

    By completing this form, you agree to receive marketing communications from PYMNTS and to the sharing of your information with our sponsor, if applicable, in accordance with our Privacy Policy and Terms and Conditions.

    The CCI imposed a penalty of nearly $11 million on Lupin, which had refused to supply drugs to Maruti & Co., a drug wholesaler in Karnataka, on the ground that the drugmaker did not have a no-objection certificate (NOC) from the Karnataka Chemists and Drugs Association. The regulator also fined KCDA $860,000 for indulging in the anti-competitive practice of restricting supply of drugs to pharmaceutical companies in Karnataka.

    A detailed investigation by the CCI found that KCDA was indulging in the anti-competitive practice of mandating an NOC.

    The regulator also found three office-bearers of KCDA and two officials of Lupin actively involved in the anti-competitive arrangement leading to the refusal of drugs to Maruti & Co. which filed the petition leading to the investigation.

    Full Content: Live Mint

    Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.